Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis

Clinical and Experimental Immunology

Volumn 156, Issue 1, 2009, Pages 69-77

  Djoba Siawaya, J F ^b   Beyers, N ^c   Van Helden, P ^b   Walzl, G ^a,b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b Faculty of Health Sciences   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Biomarkers; Cytokine; Treatment response; Tuberculosis

Indexed keywords

CINTREDEKIN BESUDOTOX; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR ALPHA; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY; TREATMENT RESPONSE; TUBERCULIN TEST;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CYTOKINES; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 61849099439     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.03875.x     Document Type: Article

References (59)

1. Cardona PJ, Ruiz-Manzano J. On the nature of Mycobacterium tuberculosis-latent bacilli. Eur Respir J 2004 24 : 1044 51.
2. Global Tuberculosis Control: Surveillance, Planning, Financing: WHO report 2008.
3. Dolin PJ, Raviglione MC, Kochi A. Global tubercolosis incidence and mortality during 1990-2000. Bull WHO 1994 72 : 213 20.
4. World Health Organization. World Health Organization fact sheet. Geneva, Switzerland : World Health Organization, 2002.
5. Enarson DE, Rieder HL, Arnadottir T, Trebucq A. Management of tuberculosis a guide for low income countries, 5th edn. Paris : IUATLD, 2000.
6. Sharma KS, Mohan A. Multidrug-resistant tuberculosis. Chest 2006 130 : 261 72.
7. Frankenstein Z, Alon U, Cohen I. The immune-body cytokine network defines a social architecture of cell interactions. Biol Direct 2006 1 : 32.
8. Zganiacz A, Santosuosso M, Wang J et al. TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest 2004 113 : 401 13.
9. Juffermans NP, Verbon A, van Deventer SJ, van Deutekom H, Speelman P, van der Poll T. Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. Am J Respir Crit Care Med 1998 157 : 1328 31.
10. + natural killer T cells in fast treatment responders. Clin Exp Immunol 2006 145 : 252 60.
11. Djoba Siawaya JF, Bapela NB, Ronacher K et al. Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. J Infect 2008 56 : 340 7.
12. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning. Data mining, inference and predicition. New York/Berlin/Heidelberg : Springer-Verlag, 2001.
13. Bothamley GH. New tests for tuberculosis: local immune responses have greater specificity. Thorax 2008 63 : 4 5.
14. Hirsch CS, Toossi Z, Johnson JL et al. Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J Infect Dis 2001 183 : 779 88.
15. Schwander S, Torres M, Sada E et al. Enhanced responses to Mycobacterium tuberculosis antigens by human alveolar lymphocytes during active pulmonary tuberculosis. J Infect Dis 1998 178 : 1434 45.
16. Finkelman FD, Morris SC. Development of an assay to measure in vivo cytokine production in the mouse. Int Immunol 1999 11 : 1811 18.
17. Lebecque S. A new job for dendritic cells. Nat Immunol 2001 2 : 830 1.
18. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol 2007 85 : 103 11.
19. Law K, Weiden M, Harkin T, Tchou-Wong K, Chi C, Rom WN. Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am J Respir Crit Care Med 1996 153 : 799 804.
20. Kiropoulos TS, Kostikas K, Oikonomidi S et al. Acute phase markers for the differentiation of infectious and malignant pleural effusions. Respir Med 2007 101 : 910 18.
21. Saltini C, Colizzi V. Soluble immunological markers of disease activity in tuberculosis. Eur Respir J 1999 14 : 485 6.
22. Azzurri A, Sow OY, Amedei A et al. IFN-[gamma]-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005 7 : 1 8.
23. Inoue Y, Nishimura K, Shiode M et al. Evaluation of serum KL-6 in patients with pulmonary tuberculosis. Tuber Lung Dis 1995 76 : 230 3.
24. Nobuoki K. Serum marker KL-6/MUCI 1 for the diagnosis and management of interstitial pneumonitis. J Med Invest 1999 46 : 151 8.
25. Yokoyama A, Kohno N, Hamada H et al. Circulating KL-6 predict the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998 158 : 1680 4.
26. Deveci F, Akbulut HH, Turgut T, Muz MH. Changes in serum cytokine levels in active tuberculosis with treatment. Mediat Inflamm 2005 2005 : 256 62.
27. Murray PJ, Wang L, Onufryk C, Tepper RI, Young RA. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J Immunol 1997 158 : 315 21.
28. Sherry B, Espinoza M, Manogue KR, Cerami A. Induction of the chemokine beta peptides, MIP-1 alpha and MIP-1 beta, by lipopolysaccharide is differentially regulated by immunomodulatory cytokines gamma-IFN, IL-10, IL-4, and TGF-beta. Mol Med 1998 4 : 648 57.
29. Sherry B, Tekamp-Olson P, Gallegos C et al. Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1 beta. J Exp Med 1988 168 : 2251 9.
30. Harris J, De Haro SA, Master SS et al. T Helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 2007 27 : 505 17.
31. Wynn TA. IL-13 effector functions Annu Rev Immunol 2003 21 : 425 56.
32. Zhou W, Hashimoto K, Moore ML et al. IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse. Microbes Infect 2006 8 : 2880 9.
33. Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM. T-cell help for cytotoxic T lymphocytes is mediated by CD 40-CD40L interactions. Nature 1998 393 : 480 3.
34. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998 16 : 111 35.
35. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000 67 : 2 17.
36. Danese S, Katz JA, Saibeni S et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003 52 : 1435 41.
37. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001 58 : 4 43.
38. Vanichakarn P, Blair P, Wu C, Freedman JE, Chakrabarti S. Neutrophil CD40 enhances platelet-mediated inflammation. Thromb Res 2008 122 : 346 58.
39. Yamauchi PS, Bleharski JR, Uyemura K et al. A role for CD40-CD40 ligand interactions in the generation of type 1 cytokine responses in human leprosy. J Immunol 2000 165 : 1506 12.
40. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 1996 4 : 283 9.
41. Florido M, Goncalves AS, Gomes MS, Appelberg R. CD40 is required for the optimal induction of protective immunity to Mycobacterium avium. Immunology 2004 111 : 323 7.
42. Noelle RJ. CD40 and its ligand in host defense. Immunity 1996 4 : 415 19.
43. Samten B, Thomas EK, Gong J, Barnes PF. Depressed CD40 ligand expression contributes to reduced gamma interferon production in human tuberculosis. Infect Immun 2000 68 : 3002 6.
44. Samten B, Wizel B, Shams H et al. CD40 ligand trimer enhances the response of CD8+ T cells to Mycobacterium tuberculosis. J Immunol 2003 170 : 3180 6.
45. Serbina NV, Jia T, Hohl TM, Pamer EG. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 2008 26 : 221 52.
46. Majumder N, Bhattacharjee S, Bhattacharyya Majumdar S et al. Restoration of impaired free radical generation and proinflammatory cytokines by MCP-1 in mycobacterial pathogenesis. Scand J Immunol 2008 67 : 329 39.
47. Lin Y, Gong J, Zhang M, Xue W, Barnes PF. Production of monocyte chemoattractant protein 1 in tuberculosis patients. Infect.Immun 1998 66 : 2319 22.
48. Rutledge BJ, Rayburn H, Rosenberg R et al. High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J Immunol 1995 155 : 4838 43.
49. Flores-Villanueva PO, Ruiz-Morales JA, Song CH et al. A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis. J Exp Med 2005 202 : 1649 58.
50. Martin TR. Lung cytokines and ARDS: Roger S. Mitchell Lecture. Chest 1999 116 : 2S 8S.
51. Goodman RB, Strieter RM, Martin DP et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996 154 : 602 11.
52. Husain N, Awasthi S, Haris M, Gupta RK, Husain M. Vascular endothelial growth factor as a marker of disease activity in neurotuberculosis. J Infect 2008 56 : 114 19.
53. Matsuyama W, Hashiguchi T, Matsumuro K, Iwami F, Hirotsu Y, Kawabata M, Arimura K, Osame M. Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis. Am J Respir Crit Care Med 2000 162 : 1120 2.
54. Alatas F, Alatas O, Metintas M, Ozarslan A, Erginel S, Yildirim H. Vascular endothelial growth factor levels in active pulmonary tuberculosis. Chest 2004 125 : 2156 9.
55. Bannerman DD, Paape MJ, Chockalingam A. Staphylococcus aureus intramammary infection elicits increased production of transforming growth factor-[alpha], [beta]1, and [beta]2. Vet Immunol Immunopathol 2006 112 : 309 15.
56. Maitre B, Boussat S, Jean D et al. Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury. Eur Respir J 2001 18 : 100 6.
57. Dehio C. Recent progress in understanding Bartonella-induced vascular proliferation. Curr Opin Microbiol 2003 6 : 61 5.
58. Vankayalapati R, Klucar P, Wizel B et al. NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen. J Immunol 2004 172 : 130 7.
59. Ohteki T. Critical role for IL-15 in innate immunity. Curr Mol Med 2002 2 : 371 80.